Patent Disputes in Genetic Material and Biotechnology: Balancing Innovation, Ethics, and Access to Medical Treatments

MARK TERRY, ESQ.

Patent disputes involving genetic material and biotechnology sit at the intersection of intellectual property, scientific innovation, public health, and ethics. Patents can reward expensive research, but overly broad exclusivity may also restrict access to testing, treatment, and foundational scientific tools.

The Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics drew an important distinction between naturally occurring DNA and laboratory-created complementary DNA. Naturally occurring gene sequences were treated as products of nature, while synthetic cDNA could remain eligible for patent protection.

Biopharmaceutical and gene-therapy companies often invest substantial resources in developing biologics and personalized treatments. Patent exclusivity can help recover those investments, but it may also contribute to high prices and limited patient access. Compulsory licensing and other public-health mechanisms remain part of the broader policy debate.

Genetically modified organisms and gene-editing tools raise similar questions. Diamond v. Chakrabarty opened the door to patents involving engineered living organisms, while newer technologies such as CRISPR continue to generate ownership disputes and ethical concerns.

Biotechnology innovators should develop patent strategies that protect genuine technical contributions while accounting for subject-matter eligibility, regulatory requirements, licensing, access considerations, and the evolving treatment of natural phenomena.